Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

A researcher in a lab coat working with a microscope, studying a biopharmaceutical drug. Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug ...

But the headline is that CagriSema allowed people to lose 20.4% of their body weight on average—better than Wegovy, but about on par with what people can achieve with Eli Lilly’s Zepbound.

Novo Nordisk recently announced results for a new weight loss candidate, CagriSema. Data from the trial ... However, this is far from the case. I'm going to break down why a recent piece of ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...

“The CagriSema study has created another untimely setback for Novo Nordisk as investors give Lilly greater credibility on the high-performance standards achieved with its next-gen Retatrutide ...